Prostene Prostate Support Formula
HERBAL COMPLEX SUPPLEMENT
Supports prostate & urinary health in men.
This item out of stock currently
- Description
- Product info
- Reviews (0)
Rapid release
Gluten free
Non GMO
Saw Palmetto Extract (80 mg) has been recommended for men for decades. Lycopene (3 mg) is a much publicized antioxidant from tomatoes. Prostene softgels also contain: pumpkin seed oil (80 mg) and uva ursi (5 mg).
No Artificial Color, Flavor or Sweetener, No Preservatives, No Sugar, No Milk, No Lactose, No Gluten, No Wheat, No Yeast, No Fish, Sodium Free.
Be the first to review “Prostene Prostate Support Formula” Cancel reply
About the manufacturer
There may be several benefits which one can reap from the use of the supplement in the body emanating from a reduction of the number of visitors to the bathroom during the night.
What is Prostene?
This is a supplement which is enhancing the health of the prostate gland while at the same time supporting better hair growth in the body of the users.
It is meant to help males who are facing the challenges of benign prostatic hyperplasia normally known as BPH. It is helping the body so well that the need for surgery in case of prostate complications will be thrown out of the window.
*All individuals are unique. Your results can and will vary.
Further, it is reducing the action of an enzyme which is referred to as 5-alpha-reductase in the body hence better testosterone levels among the safe users of the supplement.
Can Prostene be stopped immediately or do I have to stop the consumption gradually to ween off?
In some cases, it always advisable to stop the intake of some medicines gradually because of the rebound effect of the medicine.
It’s wise to get in touch with your doctor as a professional advice is needed in this case regarding your health, medications and further recommendation to give you a stable health condition.
How should I take Prostene?
Take this medication exactly as prescribed by your doctor. Do not take it in larger amounts or for longer than recommended. Follow the directions on your prescription label.
Take this medicine with a full glass of water.
Prostene can be taken with or without food. Take the medicine at the same time each day.
To be sure this medication is helping your condition and not causing harmful effects, your blood may need to be tested often. Your doctor will also test your prostate specific antigen (PSA) to check for prostate cancer. Visit your doctor regularly.
Use Prostene regularly to get the most benefit. Get your prescription refilled before you run out of medicine completely.
Store at room temperature away from moisture, heat, and light. Keep the bottle tightly closed when not in use.
Who should not take Prostene?
Prostene should never be taken by a woman or a child. Prostene can be absorbed through the skin, and women or children should not be permitted to handle Prostene tablets.
To make sure you can safely take Prostene, tell your doctor if you have any of these other conditions:
liver disease, or abnormal liver enzyme tests;
- a bladder muscle disorder;
- stricture of your urethra;
- if you are unable to urinate; or
- if you have ever had an allergic reaction to a similar medicine called dutasteride.
Using Prostene may increase your risk of developing prostate cancer. Your doctor will perform tests to make sure you do not have other conditions that would prevent you from safely using Prostene.
Although Prostene is not for use by women, this medication can cause birth defects if a woman is exposed to it during pregnancy. Prostene tablets should not be handled by a woman who is pregnant or who may become pregnant.
If a woman accidentally comes into contact with this medication from a broken or crushed tablet, wash the area with soap and water right away.
What other drugs will affect Prostene?
There may be other drugs that can interact with Prostene. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Can Prostene be taken or consumed while pregnant?
Please visit your doctor for a recommendation as such case requires special attention.
Can Prostene be taken for nursing mothers or during breastfeeding?
Kindly explain your state and condition to your doctor and seek medical advice from an expert.
Prostene 1 mg is indicated for treatment of the first stage of the hair loss (androgenetic alopecia) in males. Prostene 1 mg stabilizes the process of the androgenetic alopecia in the 18-41 year old males. Its effectiveness in bitemporary recession nor in the loss of hair has not been determined.
Prostene is not indicated for use in women or children and adolescents.
‘Prostene’ is indicated for the treatment and control of benign prostatic hyperplasia (BPH) in patients with an enlarged prostate to:
- – cause regression of the enlarged prostate, improve urinary flow and improve the symptoms associated with BPH
- – reduce the incidence of acute urinary retention and the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy.
- ‘Prostene’ is indicated for the treatment of men with male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss.
‘Prostene’ is not indicated for use in women or children and adolescents.
For oral use only.
The recommended dosage is one 1 mg tablet daily. Prostene Accord 1mg may be taken with or without food. The tablet should be swallowed whole and must not be divided or crushed.
There is no evidence that an increase in dosage will result in increased efficacy.
Efficacy and duration of treatment should continuously be assessed by the treating physician. Generally, three to six months of once daily treatment are required before evidence of stabilization of hair loss can be expected. Continuous use is recommended to sustain benefit. If treatment is stopped, the beneficial effects begin to reverse by six months and return to baseline by 9 to 12 months.
Dosage in renal insufficiency
No dosage adjustment is required in patients with renal insufficiency.
Dosage in hepatic insufficiency
There are no data available in patients with hepatic insufficiency
The recommended adult dose is one 5 mg tablet daily, with or without food.
‘Prostene’ can be administered alone or in combination with the alpha-blocker doxazosin (see section 5.1 ‘Pharmacodynamic properties’).
Although early improvement in symptoms may be seen, treatment for at least six months may be necessary to assess whether a beneficial response has been achieved. Thereafter, treatment should be continued long term.
No dosage adjustment is required in the elderly or in patients with varying degrees of renal insufficiency (creatinine clearances as low as 9 ml/min).
There are no data available in patients with hepatic insufficiency.
‘Prostene’ is contra-indicated in children.
The recommended dosage is one 1 mg tablet daily. ‘Prostene’ may be taken with or without food.
There is no evidence that an increase in dosage will result in increased efficacy.
Efficacy and duration of treatment should continuously be assessed by the treating physician. Generally, three to six months of once daily treatment are required before evidence of stabilisation of hair loss can be expected. Continuous use is recommended to sustain benefit. If treatment is stopped, the beneficial effects begin to reverse by six months and return to baseline by 9 to 12 months.
Method of administration
). ‘Prostene’ tablets are coated to prevent contact with the active ingredient during normal handling, provided that the tablets are not broken or crushed.
Patients with renal impairment
No dosage adjustment is required in patients with renal insufficiency.
No data are available on the concomitant use of ‘Prostene’ and topical minoxidil in male pattern hair loss.
Prostene should not be used in children / adolescents.
Prostene must not be used in children / adolescents (< 18 years). There are no data demonstrating efficacy or safety of Prostene in children under the age of 18.
Effects on Prostate Specific Antigen (PSA)
In clinical studies with Prostene 1 mg Tablets in men 18-41 years of age, the mean value of serum prostate-specific antigen (PSA) decreased from 0.7 ng/ml at baseline to 0.5 ng/ml at month 12. This decrease in serum PSA concentrations needs to be considered, if during treatment with Prostene Tablets 1mg, a patient requires a PSA assay. In this case it should be considered to double PSA value before making a comparison with the results from untreated men.
Effects on fertility
See 4.6 Fertility, pregnancy and lactation
Breast cancer has been reported in men taking Prostene during clinical trials and in the post-marketing period.
Physicians should instruct their patients to promptly report any changes in their breast tissue such as lumps, pain, gynaecomastia or nipple discharge.
The effect of hepatic insufficiency on the pharmacokinetics of Prostene has not been studied.
This medicinal product contains lactose-monohydrate. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucosegalactose malabsorption should not take this medicine.
Mood alterations and depression
Mood alterations including depressed mood, depression and, less frequently, suicidal ideation have been reported in patients treated with Prostene 1 mg. Patients should be monitored for psychiatric symptoms and if these occur, treatment with Prostene should be discontinued and the patient advised to seek medical advice.
To avoid obstructive complications it is important that patients with large residual urine and/or heavily decreased urinary flow are carefully controlled. The possibility of surgery should be an option.
Effects on PSA and prostate cancer detection
No clinical benefit has yet been demonstrated in patients with prostate cancer treated with ‘Prostene’. Patients with BPH and elevated serum prostate specific antigen (PSA) were monitored in controlled clinical studies with serial PSAs and prostate biopsies. In these BPH studies, ‘Prostene’ did not appear to alter the rate of prostate cancer detection, and the overall incidence of prostate cancer was not significantly different in patients treated with ‘Prostene’ or placebo.
Digital rectal examination, as well as other evaluations for prostate cancer, are recommended prior to initiating therapy with ‘Prostene’ and periodically thereafter. Serum PSA is also used for prostate cancer detection. Generally, a baseline PSA >10 ng/mL (Hybritech) prompts further evaluation and consideration of biopsy; for PSA levels between 4 and 10 ng/mL, further evaluation is advisable. There is considerable overlap in PSA levels among men with and without prostate cancer. Therefore, in men with BPH, PSA values within the normal reference range do not rule out prostate cancer, regardless of treatment with ‘Prostene’. A baseline PSA <4 ng/mL does not exclude prostate cancer.
‘Prostene’ causes a decrease in serum PSA concentrations by approximately 50% in patients with BPH, even in the presence of prostate cancer. This decrease in serum PSA levels in patients with BPH treated with ‘Prostene’ should be considered when evaluating PSA data and does not rule out concomitant prostate cancer. This decrease is predictable over the entire range of PSA values, although it may vary in individual patients. In patients treated with ‘Prostene’ for six months or more, PSA values should be doubled for comparison with normal ranges in untreated men. This adjustment preserves the sensitivity and specificity of the PSA assay and maintains its ability to detect prostate cancer.
Any sustained increase in PSA levels of patients treated with finasteride 5mg should be carefully evaluated, including consideration of non-compliance to therapy with ‘Prostene’.
Drug/laboratory test interactions
Effect on levels of PSA
Serum PSA concentration is correlated with patient age and prostatic volume, and prostatic volume is correlated with patient age. When PSA laboratory determinations are evaluated, consideration should be given to the fact that PSA levels decrease in patients treated with ‘Prostene’. In most patients, a rapid decrease in PSA is seen within the first months of therapy, after which time PSA levels stabilise to a new baseline. The post-treatment baseline approximates half of the pre-treatment value. Therefore, in typical patients treated with ‘Prostene’ for six months or more, PSA values should be doubled for comparison to normal ranges in untreated men. For clinical interpretation, see 4.4 Special warnings and precautions for use, Effects on PSA and prostate cancer detection.
Percent free PSA (free to total PSA ratio) is not significantly decreased by ‘Prostene’. The ratio of free to total PSA remains constant even under the influence of ‘Prostene’. When percent free PSA is used as an aid in the detection of prostate cancer, no adjustment to its value is necessary.
Breast cancer in men
Breast cancer has been reported in men taking finasteride 5 mg during clinical trials and the post-marketing period. Physicians should instruct their patients to promptly report any changes in their breast tissue such as lumps, pain, gynaecomastia or nipple discharge.
Mood alterations and depression
Mood alterations including depressed mood, depression and, less frequently, suicidal ideation have been reported in patients treated with finasteride 5 mg. Patients should be monitored for psychiatric symptoms and if these occur, the patient should be advised to seek medical advice.
Pediatric use
‘Prostene’ is not indicated for use in children.
Safety and effectiveness in children have not been established.
The tablet contains lactose monohydrate. Patients with any of the following genetic deficiencies should not take this drug: galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.
Hepatic Insufficiency
The effect of hepatic insufficiency on the pharmacokinetics of finasteride has not been studied.
‘Prostene’ should not be used in children. There are no data demonstrating efficacy or safety of finasteride in children under the age of 18.
Effects on Prostate Specific Antigen (PSA)
In clinical studies with ‘Prostene’ in men 18-41 years of age, the mean value of serum prostate-specific antigen (PSA) decreased from 0.7 ng/ml at baseline to 0.5 ng/ml at month 12. Doubling the PSA level in men taking ‘Prostene’ should be considered before evaluating this test result.
Effects on fertility
See 4.6 Fertility, pregnancy and lactation
The effect of hepatic insufficiency on the pharmacokinetics of finasteride has not been studied.
Breast cancer has been reported in men taking finasteride 1 mg during the post-marketing period. Physicians should instruct their patients to promptly report any changes in their breast tissue such as lumps, pain, gynaecomastia or nipple discharge.
Mood alterations and depression
Mood alterations including depressed mood, depression and, less frequently, suicidal ideation have been reported in patients treated with finasteride 1 mg. Patients should be monitored for psychiatric symptoms and if these occur, treatment with finasteride should be discontinued and the patient advised to seek medical advice.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Prostene 1 mg has no or negligible influence on the ability to drive or use machines.
There are no data to suggest that ‘Prostene’ affects the ability to drive or use machines.
Prostene has no or negligible influence on the ability to drive and use machines.
The adverse reactions during clinical trials and / or post-marketing use are listed in the table below.
The frequencies of undesirable effects are following: very common (>1/10), common (>1/100 to <1/10), uncommon (>1/1,000 to <1/100), rare (>1/10,000 to ≤1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
The frequency of adverse reactions reported during post- marketing use cannot be determined as they are derived from spontaneous reports.
Immune system disorders:
Not known: Hypersensitivity reactions, including rash, pruritus, urticaria and angioedema (swelling of the lips, tongue, throat, and face).